- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
See AlsoOP0089 PHASE 2 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED EVERY 4 WEEKS UP TO 48 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)AB1623-HPR CLINICAL CHECKLISTS IN THE REQUEST FOR ANALYSIS FOR PROFILES OF SUSPICION AS AN IMPROVEMENT OF A REFERRAL TOOL TO RHEUMATOLOGYPOS1138 A RETROSPECTIVE STUDY ON LUPUS NEPHRITIS: EXAMINING CLINICAL, SEROLOGICAL, AND PROGNOSTIC DIFFERENCES BETWEEN PEDIATRIC AND ADULT-ONSET PATIENTS IN A TERTIARY MEDICAL CENTERThe 10 NAEYC Program Standards - Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 83,Issue Suppl 1
- AB0758 CIRCULATING ADIPOKINES AND RESPONSE TO TREATMENT IN EARLY RHEUMATOID ARTHRITIS – DATA FROM THE RANDOMIZED NORD-STAR TRIAL
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
Scientific Abstracts
Publication Only
Rheumatoid arthritis
AB0758 CIRCULATING ADIPOKINES AND RESPONSE TO TREATMENT IN EARLY RHEUMATOID ARTHRITIS – DATA FROM THE RANDOMIZED NORD-STAR TRIAL
- G. K. Vasileiadis1,
- Y. Zhang1,
- T. Fatima1,
- R. F. Van Vollenhoven2,3,
- J. Lampa2,
- B. Gudbjornsson4,5,
- D. Nordström6,7,
- G. Grondal4,5,
- K. Hørslev-Petersen8,9,
- K. Lend2,3,
- M. S. Heiberg10,
- M. Lund Hetland11,12,
- M. Nurmohamed3,13,
- T. Uhlig14,15,
- T. Sokka-Isler16,
- A. Rudin1,17,
- C. Maglio1,17
- 1University of Gothenburg, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, Gothenburg, Sweden
- 2Karolinska Institute, Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Stockholm, Sweden
- 3Amsterdam University Medical Centers, Department of Rheumatology and Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands
- 4Landspitali University Hospital, Reykjavik, Iceland
- 5University of Iceland, Faculty of Medicine, Reykjavik, Iceland
- 6Helsinki University Hospital, Division of Medicine and Rheumatology, Helsinki, Finland
- 7University of Helsinki, Helsinki, Finland
- 8University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark
- 9University of Southern Denmark, Department of Regional Health Research, Odense, Denmark
- 10Diakonhjemmet Hospital, Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Oslo, Norway
- 11Rigshospitalet, Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Glostrup, Denmark
- 12University of Copenhagen, Department of Clinical Medicine, Faculty of Health Sciences, Copenhagen, Denmark
- 13Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands
- 14Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway
- 15University of Oslo, Oslo, Norway
- 16Jyväskylä Central Hospital, Department of Medicine and University of Eastern Finland, Jyväskylä, Finland
- 17Sahlgrenska University Hospital, Rheumatology Clinic, Gothenburg, Sweden
Abstract
Background: Adiponectin, leptin, and resistin are adipokines whose circulating levels are increased in people with rheumatoid arthritis (RA) compared to healthy controls. A few studies in small cohorts have investigated the role of these adipokines as biomarkers of response to anti-rheumatic treatment in RA, with inconsistent results.
Objectives: We aimed to determine if baseline levels of adiponectin, leptin, and resistin are associated with future response to anti-rheumatic treatment in people with untreated early RA.
Methods: This post-hoc analysis of the NOrdic Rheumatic Diseases Strategy Trials and Registries (NORD-STAR) trial included data from 341 individuals from Sweden with untreated newly diagnosed RA (1, 2). Participants were randomized at baseline into 4 treatment arms: methotrexate combined with prednisolone (1), certolizumab (2), abatacept (3), or tocilizumab (4). Participants were followed for up to 48 weeks. Clinical and laboratory measurements were performed at baseline, and at 8-, 12-, 24-, and 48-week follow-up. Adipokines were measured in plasma at baseline with ELISA. The primary outcome for this report is the difference in remission according to the Clinical Disease Activity Index (CDAI ≤2.8) over time up to 48 weeks stratified by median adipokine levels.
Results: As illustrated in Table 1, at baseline, participants with adiponectin levels above the median had lower BMI, higher age, and were more frequently women, whereas participants with leptin levels above the median had a higher BMI and were more frequently women. Baseline levels of adiponectin and leptin were not associated with markers of RA activity (Table 1). At baseline, participants with higher resistin levels had higher c-reactive protein (CRP) levels (29±36 vs 17±22 mg/L; p<0.001), swollen joint count (9±5 vs 8±5; p=0.03), and higher Disease Activity Score of 28 joints based on CRP (5.3±1.0 vs 5.0±1.1; p=0.03) compared to participants with lower resistin (Table 1). Participants with baseline adipokine levels above the median and those with adipokine levels below the median had similar mean CDAI and changes in CDAI throughout follow-up for up to 48 weeks (Figure 1A and B). Kaplan-Meier curves for CDAI remission showed no difference in the likelihood of achieving remission between participants with high vs low adiponectin and those with high vs low resistin at baseline (Figure 1C). Participants whose baseline leptin levels were above the median had a reduced likelihood of achieving remission compared to those whose baseline leptin levels were below the median (Figure 1C). However, cox proportional hazards models adjusted for sex, baseline age, body mass index (BMI), smoking, and CDAI did not show any effect of baseline adiponectin, leptin, and resistin levels on the likelihood of achieving CDAI remission (adiponectin: HR 1.08, 95% CI 0.80-1.45, p=0.62; leptin: HR 0.89, 95% CI 0.64-1.26, p=0.52; resistin: HR 0.86, 95% CI 0.65-1.13, p=0.26).
- Download figure
- Open in new tab
- Download powerpoint
Figure 1.
Adipokines effect on CDAI, changes in CDAI, and CDAI remission. (A, B): Mean values, and level changes for CDAI. p values were calculated with general linear model adjusted for sex, baseline age, BMI, and current smoking. (C): Kaplan-Meier curves for CDAI remission showing log rank p value and hazards ratio (95% CI) with p value from Cox proportional hazards model adjusted for sex, baseline age, BMI, current smoking, and CDAI.
- Download figure
- Open in new tab
- Download powerpoint
Conclusion: Baseline adiponectin, leptin, and resistin levels are not associated with the likelihood of achieving CDAI remission over 48 weeks in this large trial of first-line treatments in early RA. Our results underscore the importance of adjusting for confounders when studying the effects of adipokines on RA outcomes, as circulating adipokine levels are highly dependent on other factors, such as BMI and sex.
REFERENCES: [1] Hetland ML, et al. BMJ (Clinical research ed). 2020;371:m4328.
[2] Østergaard M, et al. Ann Rheum Dis. 2023;82(10):1286-95.
Acknowledgements: NIL.
Disclosure of Interests: Georgios K. Vasileiadis: None declared, Yuan Zhang: None declared, Tahzeeb Fatima: None declared, Ronald F. van Vollenhoven: None declared, Jon Lampa: None declared, Bjorn Gudbjornsson Lectures fees from Novartis and Nordic Pharma, Consulting fee from Novartis, Dan Nordström Personal consultancy fees from BMS, Lilly, MSD, Novartis, Pfizer and UCB, Personal study grant from MSD, outside current work, Gerdur Grondal: None declared, Kim Hørslev-Petersen: None declared, Kristina Lend: None declared, Marte S Heiberg: None declared, Merete Lund Hetland Research grants from AbbVie, iogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Foundation, MSD, Pfizer, Roche, Samsung Biopies, Sandoz, Novartis, Nordforsk to institution; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer, Medac, Sandoz paid to institution; participation on a Data Safety Monitoring Board or Advisory Board from Abbvie paid to institution. Chaired the steering committee of the Danish Rheumatology Quality Registry (DANBIO, DRQ), which receives public funding from the hospital owners and funding from pharmaceutical companies. Co-chair of EuroSpA, which generates real-world evidence of treatment of psoriatic arthritis and axial spondylarthritis based on secondary data and is partly funded by Novartis., Michael Nurmohamed: None declared, Till Uhlig Personal fees from Galapagos, Lilly, Pfizer, UCB outside the submitted work., Tuulikki Sokka-Isler Research grant from Amgen paid to the institution, honoraria from Nordic Pharma, Anna Rudin: None declared, Cristina Maglio: None declared.
- Remission
- Prognostic factors
- Disease-modifying Drugs (DMARDs)
- Randomized controlled trial
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Remission
- Prognostic factors
- Disease-modifying Drugs (DMARDs)
- Randomized controlled trial
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens